Problems in the therapy of ovarian carcinoma with gestagen-acting hormones
Krafft, W.; Steuckart, R.; Preibsch, W.; Behling, H.; Brückmann, D.; Schirmer, A.; Kademann, J.
Zentralblatt für Gynakologie 105(9): 560-565
1983
ISSN/ISBN: 0044-4197 PMID: 6880471 Document Number: 220436
Our experience concerning the effectivity of progestogens (Noräthisteron 50 mg per os daily) in cases of advanced ovarian cancer is reported. Group 1 (25 pat.) suffering from less sensitive ovarian cancer was treated with cytotoxic drugs and hormones. The survival chance of combined hormonal and tumourchemotherapy was nearly 40% better than the survival chance with chemotherapy alone. In Group 2 (14 pat.) suffering from secondary resistant ovarian cancer chemotherapy was stopped, but the patients received hormones only. There were no better survival rate in this group. The biomolecular background is explained.